Selectively Delivering Pharmaceutical Agents to the Liver

Ligand's LTP™ technology is a novel prodrug technology platform designed to selectively deliver a range of active pharmaceutical agents to the liver. It works by chemically modifying a biologically active molecule into an inactive prodrug form that will be administered and later activated in the liver by certain enzymes mainly expressed in the liver. The technology can be used to improve activity and/or safety of an existing drug, or to develop new agents to treat liver diseases or diseases caused by homeostasis imbalance of circulating biomolecules controlled by the liver, such as lipids. LTP™ is especially applicable to metabolic and cardiovascular diseases. LTP™ has expanded chemical class applicability and eliminates the formation of certain by-products that may occur with other targeting technologies.